Bruker Corporation · NASDAQ:BRKR
Bruker — 2024 J.P. Morgan Healthcare Conference
25 slides from Bruker's conference presentation, Jan 8, 2024
Slide 1: Emerging Leader of the Post-Genomic Era
IN N OVATION WITH IN TEG RIT Y Bruker Corporation (Nasdaq: BRKR) Emerging Leader of the Post-Genomic Era Frank H. Laukien Bruker Chairman, President & CEO San Francisco, CA - January 8, 2024 2024 JP Morgan Healthcare Conference
Slide 2: Safe Harbor Statement
BRUKER CORPORATION Safe Harbor Statement Any statements contained in this presentation which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934,
Slide 3: Dual strategy of Project Accelerate 2.0 and Operational Excellence works
BRUKER’S TRANSFORMATION INTO A FAST GROWTH COMPANY Dual strategy of Project Accelerate 2.0 and Operational Excellence works Project Accelerate 2.0 Initiatives Operational Excellence ▪ Pull up growth and EPS ▪ Push up market share, gross margin ▪ Re-positioning Bruker for high-growth, high- ▪ Bruker
Slide 4: Key Strategy Pillar: Operational Excellence & Productivity Investments
BRUKER’S TRANSFORMATION INTO A FAST GROWTH COMPANY Key Strategy Pillar: Operational Excellence & Productivity Investments ▪ Excellence in Operations, Commercial and Product R&D ▪ Driving growth, expanding gross and operating margins organically ▪ Proven progress and foundation for further investment
Slide 5: Major R&D Investments Advancing Purposeful Innovation
BRUKER’S TRANSFORMATION INTO A FAST GROWTH COMPANY Major R&D Investments Advancing Purposeful Innovation R&D AS % OF REVENUE Industry-leading Strategic R&D Investments: 10% 10% 9% ▪ Drives product innovation, #1 or #2 positions, growth, margins and EPS ▪ Fast growth in proteomics, spatial biology, I
Slide 6: Unique capabilities: NMR and EPR as Cleantech Analytical Techniques
BRUKER’S TRANSFORMATION INTO A FAST GROWTH COMPANY Unique capabilities: NMR and EPR as Cleantech Analytical Techniques Example: Battery Value Chain - Research, Production & Recycling Mining Materials Cell Packing Integration Recycling Electrode Production Mixing Coating Drying Solvent Calendering Sl
Slide 7: Unique capabilities: MALDI Biotyper with Novel Applications
BRUKER’S TRANSFORMATION INTO A FAST GROWTH COMPANY Unique capabilities: MALDI Biotyper® with Novel Applications Installed Base Grows Steadily, >50% Recurring Revenues ▪ Leader in microbial ID by proteomic fingerprinting in clinical and applied markets ▪ Faster and more cost-effective ID of bacteria
Slide 8: Core innovation: Advancing Materials Science & Clean-Tech Research
BRUKER’S TRANSFORMATION INTO A FAST GROWTH COMPANY Core innovation: Advancing Materials Science & Clean-Tech Research Bruker materials science research and testing solutions drive process and product improvements Applications in energy storage, drug delivery and additive manufacturing D6 PHASERTM X-
Slide 9: Unique capabilities: Semiconductor Metrology for Artificial Intelligence
BRUKER’S TRANSFORMATION INTO A FAST GROWTH COMPANY Unique capabilities: Semicondutor Metrology for Artificial Intelligence Enables R&D and QC for novel CPU & GPU Chips, HBM Chips, Systems on Chip (Soc), FPGAs XRD Enables Next-Gen Chip Manufacturing Advanced QC for 3D Chips Packaging • 3 nm logic mov
Slide 10: New Scientific Software Initiative: Bringing Instruments and Data into Holistic Lab Workflows
BRUKER’S TRANSFORMATION INTO A FAST GROWTH COMPANY New Scientific Software Initiative: Bringing Instruments and Data into Holistic Lab Workflows New BioSpin Integrated Data Solutions (IDS) Division IDS Scientific Software ➢ Vendor independent integrated data solutions Scientific Data Analytical data
Slide 11: New Opportunities: BEST Cleantech Technologies
BRUKER’S TRANSFORMATION INTO A FAST GROWTH COMPANY New Opportunities: BEST Cleantech Technologies ▪ Growing Cleantech markets for differentiated BEST cleantech tools ▪ BEST Cleantech technologies for future fusion power and next-gen offshore wind turbine prototypes Emerging Opportunity: Fusion Resea
Slide 12: Project Accelerate & Operational Excellence: Disciplined entrepreneurialism at work
BRUKER’S TRANSFORMATION INTO A FAST GROWTH COMPANY Project Accelerate & Operational Excellence: Disciplined entrepreneurialism at work • Bruker Management Process and culture of Disciplined Entrepreneurialism drive profitable growth • Successful transformation into a fast growth company: • On track
Slide 13: First 1.2 GHz NMR in U.S. at The Ohio State University
Q4 2023 UPDATE First 1.2 GHz NMR in U.S. at The Ohio State University ▪ Milestone in advancing US life science and materials research infrastructure, with leadership and funding by National Science Foundation ▪ Study of advanced materials (e.g., for batteries) ▪ Research structure and dynamics of bi
Slide 14: Expanding Portfolio via Acquisitions
Q4 2023 UPDATE Expanding Portfolio via Acquisitions Nion LLC for Leading High Performance Scanning Tornado Spectral Systems for Biopharma PAT Transmission Electron Microscopes Twisted bilayer graphene HyperFlux™ PRO Plus Process Guardian™ Raman system Raman spectrometer Nion HERMES™ 100 ❖ Acquired i
Slide 15: YTD Q3 2023: Robust Organic Revenue Growth & EPS Growth
Q4 2023 UPDATE YTD Q3 2023: Robust Organic Revenue Growth & EPS Growth Healthy Preliminary Q4-23 Revenue Growth; Solid FY24 Outlook YTD Q3-23A Financials (year-over-year) Q4-23E Preliminary Estimates; FY24E Outlook ❖ Revenue increased ~$288M, up +15.8% ▪ Organic revenue growth +13.9% ❖ Q4 2023 Preli
Slide 16: Leading timsTOF Platform for Proteomics and other key Multiomics fields
BRUKER – AN EMERGING LEADER OF THE POST-GENOMIC ERA Leading timsTOF® Platform for Proteomics and other key Multiomics fields Leading Solutions for Single-Cell, Spatial, Structural, Quantitative & Interaction Biology ig h ts e I n s Dis e as Proteins, PTMs, an d s B iology Lipids, Glycans & Metabolit
Slide 17: Very Large TAMs and High Secular Growth in Proteomics & Spatial Biology
BRUKER – AN EMERGING LEADER OF THE POST-GENOMIC ERA Very Large TAMs and High Secular Growth in Proteomics & Spatial Biology Essential Complex Virtuous Cycle Proteins and metabolites ~21k genes, yet millions of Ever more sensitive instruments and powerful perform most functions in proteoforms, infini
Slide 18: timsTOF Platform Advancing 4D-Proteomics
BRUKER – AN EMERGING LEADER OF THE POST-GENOMIC ERA timsTOF Platform Advancing 4D-Proteomics ❖ Unmatched Robustness (~60 SPD – 200 SPD) timsTOF HT: More than 100,000 ❖ Unparalleled Duty Cycle (PASEF, diaPASEF, prmPASEF, capsPASEF) unique peptides identified with ❖ High-Throughput Omics (5min, 20min
Slide 19: Functional Structural Biology: Understanding Disease with GHz NMR
BRUKER – AN EMERGING LEADER OF THE POST-GENOMIC ERA Functional Structural Biology: Understanding Disease with GHz NMR NMR in (Un-)structural Biology NMR in Pharmacology Intrinsically Disordered Proteins (IDPs) GPCRs as Key Drug Targets ▪ IDPs implicated in protein aggregation in ▪ NMR key to G-Prote
Slide 20: Canopy CellScape System – Truly Quantitative Spatial Biology
BRUKER – AN EMERGING LEADER OF THE POST-GENOMIC ERA Canopy CellScape® System – Truly Quantitative Spatial Biology for Cancer Research, Immuno-Oncology, Neuroscience CellScape ® Platform Differentiating Why You Should Differentiated quantitative performance in spatial proteomics Truth Matters Really
Slide 21: Bruker Cellular Analysis: Beacon Accelerates Discovery of Antibodies and Cell-Based Cancer Therapies
BRUKER – AN EMERGING LEADER OF THE POST-GENOMIC ERA Bruker Cellular Analysis: Beacon® Accelerates Discovery of Antibodies and of Cell-Based Cancer Therapies Leveraging the unique Beacon (former Berkeley Lights) platform: ▪ Development of T cell receptor T cell (TCR-T) and chimeric antigen receptor T
Slide 22: Bruker Cellular Analysis: Beacon Enables Potential Breakthroughs in Vaccine Development
BRUKER – AN EMERGING LEADER OF THE POST-GENOMIC ERA Bruker Cellular Analysis: Beacon® Enables Potential Breakthroughs in Vaccine Development Dr. Facundo Batista, MIT professor, Ragon Institute: “…HIV and malaria are two of the deadliest ▪ Focus on B cells and antibody responses in new vaccination st
Slide 23: Enabling Post-Genomic Era Research, Drug Discovery and Diagnostics
BRUKER – AN EMERGING LEADER OF THE POST-GENOMIC ERA Enabling Post-Genomic Era Research, Drug Discovery and Diagnostics Post-Genomic MALDI Biotyper Life-Science Tools Microbiology GHz-NMR Functional 2022 Bruker >25% and Diagnostics Structural Biology Revenue Mix >$650M revenue p.a. timsTOF® 4D-Proteo
Slide 24: Emerging Leadership of the Post-Genomic Era
BRUKER – AN EMERGING LEADER OF THE POST-GENOMIC ERA Dual strategy of Project Accelerate 2.0 and Operational Excellence works Project Accelerate 2.0 Initiatives Operational Excellence ▪ Pull up growth and EPS ▪ Push up market share, gross margin ▪ Re-positioning Bruker for high-growth, ▪ Bruker Manag
Slide 25: Innovation with Integrity
Innovation with Integrity